Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1331 to 1340 of 2587 total matches.

Addendum: Bupropion Safety in Pregnancy

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
Addendum: Bupropion Safety in Pregnancy Volume 66 (Issue 1699) April 1, 2024 Our December 11 ...
Our December 11, 2023 article on Drugs for Depression included a single sentence on the safety of bupropion use during pregnancy: "The safety of bupropion during pregnancy has not been established; data from a bupropion pregnancy registry suggested a possible increase in cardiac malformations." A reader asked us to provide more information.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):56   doi:10.58347/tml.2024.1699c |  Show IntroductionHide Introduction

In Brief: Esomeprazole Strontium

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014  (Issue 1447)
data in those popu- Table 1. Oral Proton Pump Inhibitors Drug Usual Dosage1,2 Cost3 Dexlansoprazole ...
The FDA has approved the proton pump inhibitor (PPI) esomeprazole strontium for use in adults for the same indications as esomeprazole magnesium (Nexium): treatment of gastroesophageal reflux disease (GERD), prevention of NSAID-induced gastric ulcers, eradication of Helicobacter pylori, and treatment of pathological hypersecretory conditions. It was first marketed in December 2013 as a branded drug (Esomeprazole Strontium) and a month later as a generic drug.Strontium is incorporated into bone. It is not recommended for use in children or during pregnancy because of the absence of safety data...
Med Lett Drugs Ther. 2014 Jul 21;56(1447):64 |  Show IntroductionHide Introduction

In Brief: New Polio Vaccination Guidance for Travelers

   
The Medical Letter on Drugs and Therapeutics • Sep 01, 2014  (Issue 1450)
Letter® on Drugs and Therapeutics Objective Drug Reviews Since 1959 Volume 56 September 1, 2014 ...
Wild poliovirus has circulated during the previous 12 months in Cameroon, Equatorial Guinea, Ethiopia, Iraq, Israel (also the West Bank and Gaza), Somalia, and Syria, as well as in those countries where polio is still endemic (Afghanistan, Nigeria, and Pakistan). The World Health Organization (WHO) has declared a public health emergency related to the possible spread of polio from affected countries. In response, the Centers for Disease Control and Prevention (CDC) has issued interim guidance for US residents planning travel to and from these countries.Vaccine Recommendations – All travelers...
Med Lett Drugs Ther. 2014 Sep 1;56(1450):84 |  Show IntroductionHide Introduction

ColciGel - A Homeopathic Colchicine Gel for Gout

   
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016  (Issue 1485)
consist of very large dilutions of "proven" substances. Serial dilutions of 1:10 are designated ...
Homeopathic drugs characteristically consist of very large dilutions of "proven" substances. Serial dilutions of 1:10 are designated by the Roman numeral X. ColciGel (Gensco), a prescription homeopathic gel containing a 10,000-fold dilution of colchicine (colchicinum 4X), is now being marketed for topical treatment and prophylaxis of gout.
Med Lett Drugs Ther. 2016 Jan 4;58(1485):5-6 |  Show IntroductionHide Introduction

In Brief: Obecabtagene Autoleucel (Aucatzyl) - Another CAR-T Cell Immunotherapy for ALL (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024  (Issue 1718)
) and brexucabtagene auto-leucel (Tecartus) were approved earlier for the same indication.1,2 THE PRODUCT — Aucatzyl ...
Obecabtagene autoleucel (Aucatzyl – Autolus), a CD19-directed genetically modified autologous T cell immunotherapy, has been approved by the FDA for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults. The CAR T-cell immunotherapy products tisagenlecleucel (Kymriah) and brexucabtagene auto-leucel (Tecartus) were approved earlier for the same indication.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):e208   doi:10.58347/tml.2024.1718f |  Show IntroductionHide Introduction

The Reflotron For Office Chemistry

   
The Medical Letter on Drugs and Therapeutics • Oct 06, 1989  (Issue 802)
for the Ektachem System DT60 and DTSC. Reflotron test strips cost $1.23 to $1.87 each, compared to $1.25 to $2.10 ...
The Reflotron (Boehringer Mannheim), a desk-top colorimetric reflectance analyzer that weighs 12 pounds, can do clinical chemistry tests on 30 l of whole blood, plasma or serum, using multilayered strips containing dry chemicals. A single test takes two to three minutes.
Med Lett Drugs Ther. 1989 Oct 6;31(802):90-1 |  Show IntroductionHide Introduction

Ethanolamine Oleate For Esophageal Varices

   
The Medical Letter on Drugs and Therapeutics • Nov 03, 1989  (Issue 804)
Engl J Med, 320:1393, 1469, May 25 and June 1, 1989). Ethanolamine oleate 5% (Ethamolin − Glaxo ...
Endoscopic injection of sclerosing agents is now widely accepted as a primary treatment for bleeding esophageal varices (J Terblanche et al, N Engl J Med, 320:1393, 1469, May 25 and June 1, 1989). Ethanolamine oleate 5% (Ethamolin - Glaxo), a sclerosing agent that has been available in Canada and abroad for many years, was recently approved for this indication by the US Food and Drug Administration (FDA).
Med Lett Drugs Ther. 1989 Nov 3;31(804):99-100 |  Show IntroductionHide Introduction

Interferon for Chronic Viral Hepatitis

   
The Medical Letter on Drugs and Therapeutics • Jan 12, 1990  (Issue 809)
Intern Med, 147:1577, 1987; M Schultz et al, Lancet, 1:1452, 1989). The Medical Letter, Vol. 32 (Issue ...
Recombinant alpha interferon has been marketed in the USA for treatment of hairy-cell leukemia, genital warts, and AIDS-related Kaposi's sarcoma (Medical Letter, 28:78, 1986; 30:70, 1988). Recent reports indicate it may also be useful for treatment of chronic viral hepatitis. Recombinant alpha interferon is available as alfa-2a (Roferon-A - Roche) or alfa-2b (Intron A - Schering), which are identical except for one amino acid.
Med Lett Drugs Ther. 1990 Jan 12;32(809):1-2 |  Show IntroductionHide Introduction

Tribenzor for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 2010  (Issue 1346)
to control their blood pressure.1 Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment ...
Many patients with hypertension require more than one drug to control their blood pressure. Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines the calcium channel blocker amlodipine (Norvasc, and others), the angiotensin receptor blocker (ARB) olmesartan (Benicar)and the most commonly prescribed diuretic, hydrochlorothiazide (HCTZ). Tribenzor is not approved for initial therapy, but is recommended for patients not adequately controlled on any 2-drug combination of a calcium channel blocker, an ARB or a diuretic.
Med Lett Drugs Ther. 2010 Sep 6;52(1346):70-1 |  Show IntroductionHide Introduction

Dalfampridine (Ampyra) for MS

   
The Medical Letter on Drugs and Therapeutics • Sep 20, 2010  (Issue 1347)
(Copaxone), mitoxantrone (Novantrone) and natalizumab (Tysabri).1 Rituximab (Rituxan) and alemtuzumab ...
The FDA has approved the use of dalfampridine (4-aminopyridine; Ampyra – Acorda), a potassium channel blocker, to improve walking speed in patients with multiple sclerosis (MS). Walking speed is considered a reliable clinical measure of impairment in patients with MS.
Med Lett Drugs Ther. 2010 Sep 20;52(1347):73-4 |  Show IntroductionHide Introduction